Standout Papers

Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, do... 2023 2026 2024126
  1. Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial (2023)
    Stephen A. Harrison, Juan P. Frías et al. ˜The œLancet. Gastroenterology & hepatology

Immediate Impact

7 by Nobel laureates 6 from Science/Nature 67 standout
Sub-graph 1 of 21

Citing Papers

Steatotic liver disease
2024 Standout
Non-alcoholic fatty liver disease
2021 Standout
16 intermediate papers

Works of Reshma Shringarpure being referenced

Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
2023 Standout
CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients
2019
and 7 more

Author Peers

Author Last Decade Papers Cites
Reshma Shringarpure 1097 2889 1021 68 4.8k
Gretchen J. Darlington 1251 5339 1369 91 8.7k
P D Berk 517 2016 534 69 4.0k
Andrew N. Billin 780 3642 185 74 5.1k
Mary Selak 924 4381 452 55 7.3k
Harald Esterbauer 748 2641 370 94 5.4k
J K Boyles 1037 2708 430 42 6.5k
Bart van de Sluis 927 3379 421 95 7.5k
Thomas Gelehrter 216 2266 1039 106 4.7k
Robert B. Stein 763 4045 208 91 6.6k
Masaya Nagao 456 2506 2807 104 7.0k

All Works

Loading papers...

Rankless by CCL
2026